Regnante Keith 4
4 · Keros Therapeutics, Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Keros Therapeutics CFO Keith Regnante Sells 4,739 Shares
What Happened Keith Regnante, Chief Financial Officer of Keros Therapeutics (KROS), disposed of 4,739 shares on 2026-02-18 in an open-market sale with a weighted-average price of $16.35, generating approximately $77,483. The sale was an automatic "sell-to-cover" to satisfy tax withholding related to vested restricted stock units, not a discretionary market-timing sale.
Key Details
- Transaction date: 2026-02-18 (reported on Form 4 filed 2026-02-20; filing appears timely)
- Shares sold: 4,739; weighted-average price: $16.35; total proceeds ≈ $77,483
- Price range for the multiple trades: $16.05 to $16.65 (per footnote)
- Reason/code: sell-to-cover for tax withholding (automatic; not at insider’s discretion)
- Shares owned after transaction: not disclosed in the provided filing
- Footnote offer: insider will provide full breakdown of number of shares sold at each price upon request
Context Sell-to-cover transactions are common when restricted stock units vest and typically reflect tax-liability management rather than a directional bet on the company. This transaction should be viewed as routine tax-related selling, not necessarily an indicator of the CFO’s view on Keros Therapeutics’ stock.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-18$16.35/sh−4,739$77,483→ 39,261 total
Footnotes (2)
- [F1]The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.